


or a pharmacologically acceptable salt thereof,

wherein R_1 , R_2 , R_3 or R_4 [is] are independently selected from the group consisting of a peptide of sixteen amino acids, carboxyl group, methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, secondary butyl group, tertiary butyl group, pentyl group, isopentyl group, neopentyl group, fluorine, chlorine, bromine, iodine, and hydrogen, and wherein when said agent is adapted for the treatment of sunburn, the agent is not zinc picolinate.

18. (Once Amended) A pharmacologically active metal ion chelating agent adapted for [the] treatment of a disease, disorder, or condition selected from the group consisting of hepatitis C infections, angiogenesis, sun burn, inflammation associated with acne, [decreased immune function,] metastatic colon cancer and upper respiratory infections, wherein the disease, disorder or condition is mediated by a protein having a metal ion-protein complex, the agent having the following structure:




or a pharmacologically acceptable salt thereof,

wherein R_1 , R_2 , or R_4 [is] are independently selected from the group consisting of a peptide of sixteen amino acids, carboxyl group, methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, secondary butyl group, tertiary butyl group, pentyl group, isopentyl group, neopentyl group, fluorine, chlorine, bromine, iodine, and hydrogen; and

R_3 is a butyl group.


21. (Once Amended) A method for [the treatment of] comprising administering an effective amount of a pharmaceutical composition comprising a metal ion chelating agent to an individual having at least one disease, disorder or condition selected from the group consisting of [decreased immune function,] metastatic colon cancer, hepatitis C infections, angiogenesis, sun burn, and upper respiratory infections, [comprising the administration of an effective amount of a pharmaceutical composition comprising a] the metal ion chelating agent represented by the following structure:



or a pharmacologically acceptable salt thereof,

wherein R₁, R₂, R₃, or R₄ [is] are independently selected from the group consisting of a peptide of sixteen amino acids, carboxyl group, methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, secondary butyl group, tertiary butyl group, pentyl group, isopentyl group, neopentyl group, fluorine, chlorine, bromine, iodine, and hydrogen.


39. (Once Amended) A method comprising administering an effective amount of a pharmaceutical composition comprising a metal ion chelating agent to an individual having [for the treatment of] at least one disease, disorder or condition selected from the group consisting of [decreased immune function,] metastatic colon cancer, hepatitis C infections, angiogenesis, sun burn, inflammation associated with acne and upper respiratory infection, [comprising the administration of an effective amount of a pharmaceutical composition comprising a] the metal ion chelating agent represented by the following structure:



or a pharmacologically acceptable salt thereof,

wherein R_1 , R_2 , or R_4 [is] are independently selected from the group consisting of a peptide of sixteen amino acids, carboxyl group, methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, secondary butyl group, tertiary butyl group, pentyl group, isopentyl group, neopentyl group, fluorine, chlorine, bromine, iodine and hydrogen; and R_3 is a butyl group.

43. (Once Amended) A systemic preparation comprising approximately 1% to approximately 100% metal ion chelating agent and a pharmacologically acceptable [route of administration] carrier, wherein said metal ion chelating agent is represented by the following structure:




or a pharmacologically acceptable salt thereof,

wherein R_1 , R_2 , R_3 or R_4 [is] are independently selected from the group consisting of a peptide of sixteen amino acids, carboxyl group, methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, secondary butyl group, tertiary butyl group, pentyl

group, isopentyl group, neopentyl group, fluorine, chlorine, bromine, iodine, and hydrogen, and wherein said agent is not zinc picolinate.


48. (Once Amended) An intranasal solution comprising [in the range between] from about 0.01 mM to about 50 mM metal ion chelating agent and at least one pharmacologically suitable isotonic vehicle, said metal ion chelating agent represented by the following structure:



or a pharmacologically acceptable salt thereof,

wherein R₁, R₂, R₃ or R₄ [is] are independently selected from the group consisting of a peptide of sixteen amino acids, carboxyl group, methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, secondary butyl group, tertiary butyl group, pentyl group, isopentyl group, neopentyl group, fluorine, chlorine, bromine, iodine, and hydrogen, and wherein said agent is not zinc picolinate.


59. (Once Amended) A formulation adapted for the treatment of sunburn comprising [in the range of] from [between] about 1% to about 99% metal ion chelating agent and a topical lotion, wherein said metal ion chelating agent is represented by the following formula:



or a pharmacologically acceptable salt thereof,

wherein R₁, R₂, R₃ or R₄ [is] are independently selected from the group consisting of a peptide of sixteen amino acids, carboxyl group, methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, secondary butyl group, tertiary butyl group, pentyl group, isopentyl group, neopentyl group, fluorine, chlorine, bromine, iodine, and hydrogen, and wherein said agent is not zinc picolinate.

63. (Once Amended) A formulation adapted for the treatment of inflammation associated with acne and sunburn comprising [in the range between] from about 1% to about 99% metal ion chelating agent and a topical lotion, wherein said metal ion chelating agent is represented by the following [formula] structure:




or a pharmacologically acceptable salt thereof,

wherein R₁, R₂, or R₄ is selected from the group consisting of a peptide of sixteen amino acids, carboxyl group, methyl group, ethyl group, propyl group, isopropyl group, butyl group,

isobutyl group, secondary butyl group, tertiary butyl group, pentyl group, isopentyl group, neopentyl group, fluorine, chlorine, bromine, iodine, and hydrogen; and

R₃ is a butyl group.


65. (Once Amended) An ophthalmic preparation adapted for the control of angiogenesis comprising in the range between about 0.01% to about 99% metal ion chelating agent and a pharmacologically acceptable carrier, wherein said metal ion chelating agent is represented by the following formula:



or a pharmacologically acceptable salt thereof,

wherein R₁, R₂, R₃ or R₄ [is] are independently selected from the group consisting of a peptide of sixteen amino acids, carboxyl group, methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, secondary butyl group, tertiary butyl group, pentyl group, isopentyl group, neopentyl group, fluorine, chlorine, bromine, iodine, and hydrogen.


69. (Once Amended) An ophthalmic preparation adapted for the control of angiogenesis comprising [in the range between] from about 0.01% to about 99% metal ion chelating agent and a pharmacologically acceptable carrier, wherein said metal ion chelating agent is represented by the following formula:



or a pharmacologically acceptable salt thereof,

wherein R_1 , R_2 , or R_4 [is] are independently selected from the group consisting of a peptide of sixteen amino acids, carboxyl group, methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, secondary butyl group, tertiary butyl group, pentyl group, isopentyl group, neopentyl group, fluorine, chlorine, bromine, iodine, and hydrogen; and R_3 is a butyl group.


70. (Once Amended) A lavage comprising [up to about 99% of] at least one metal ion chelating agent represented by the following structure:



or a pharmacologically acceptable salt thereof,

wherein R_1 , R_2 , R_3 or R_4 [is] are independently selected from the group consisting of a peptide of sixteen amino acids, carboxyl group, methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, secondary butyl group, tertiary butyl group, pentyl group, isopentyl group, neopentyl group, fluorine, chlorine, bromine, iodine, and hydrogen.

74. (Once Amended) A lavage comprising [up to about 99% of] at least one metal ion chelating agent represented by the following structure:




or a pharmacologically acceptable salt thereof,

wherein R₁, R₂, or R₄ [is] are independently selected from the group consisting of a peptide of sixteen amino acids, carboxyl group, methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, secondary butyl group, tertiary butyl group, pentyl group, isopentyl group, neopentyl group, fluorine, chlorine, bromine, iodine, and hydrogen; and

R₃ is a butyl group.

75. (Once Amended) A preservative comprising [less than about 0.025%] a metal ion chelating agent, said metal ion chelating agent represented by the following structure:




or a pharmacologically acceptable salt thereof,

wherein R₁, R₂, R₃ or R₄ [is] are independently selected from the group consisting of a peptide of sixteen amino acids, carboxyl group, methyl group, ethyl group, propyl group,

isopropyl group, butyl group, isobutyl group, secondary butyl group, tertiary butyl group, pentyl group, isopentyl group, neopentyl group, fluorine, chlorine, bromine, iodine, and hydrogen.

78. (Once Amended) A preservative comprising [less than about 0.025%] a metal ion chelating agent, said metal ion chelating agent represented by the following structure:




or a pharmacologically acceptable salt thereof,

wherein R₁, R₂, or R₄ [is] are independently selected from the group consisting of a peptide of sixteen amino acids, carboxyl group, methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, secondary butyl group, tertiary butyl group, pentyl group, isopentyl group, neopentyl group, fluorine, chlorine, bromine, iodine, and hydrogen; and

R₃ is a butyl group.

79. (Once amended) A method of preserving an item [to be preserved] comprising contacting the item with a metal ion chelating agent [with said item], said metal ion chelating agent represented by the following structure:




or a pharmacologically acceptable salt thereof,

wherein R₁, R₂, R₃ or R₄ [is] are independently selected from the group consisting of a peptide of sixteen amino acids, carboxyl group, methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, secondary butyl group, tertiary butyl group, pentyl group, isopentyl group, neopentyl group, fluorine, chlorine, bromine, iodine, and hydrogen.

81. (once amended) The method of claim 79 wherein said step of contacting said item with said metal ion chelating agent [with an item to be preserved] comprises contacting said item with a composition comprising [less than about 0.025%] said metal ion chelating agent [with said item to be preserved] in a concentration of less than about 0.025%, by weight.

83. (once amended) A method of preserving an item [to be preserved] comprising contacting said item with said metal ion chelating agent [with an item to be preserved], said metal ion chelating agent represented by the following structure:



or a pharmacologically acceptable salt thereof,

wherein R₁, R₂, or R₄ [is] are independently selected from the group consisting of a peptide of sixteen amino acids, carboxyl group, methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, secondary butyl group, tertiary butyl group, pentyl group, isopentyl group, neopentyl group, fluorine, chlorine, bromine, iodine, and hydrogen; and

R₃ is a butyl group.

IN THE SPECIFICATION: